BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Low SLC22A7 expression in noncancerous liver promotes hepatocellular carcinoma occurrence - a prospective study

Dataset: Low SLC22A7 expression in noncancerous liver promotes hepatocellular carcinoma occurrence - a prospective study

Background & Aims: The recurrence determines the postoperative prognosis of patients with hepatocellular carcinoma (HCC). It is unknown...

Registered by ArrayExpress Uploader
View Dataset

Background & Aims: The recurrence determines the postoperative prognosis of patients with hepatocellular carcinoma (HCC). It is unknown whether de novo HCCs derive from the liver with disability of an organic anion transport. This study was designed to elucidate the link between such transporters and the multicentric occurrence (MO) after radical hepatectomy. Results: SLC22A7 expression was the best predictor of metastasis-free survival (MFS) as judged by the GA (Fold, 0.726; P=0.001). High SLC22A7 gene expression in noncancerous tissue prevent HCC occurrence after hepatectomy (Odds Ratio (OR), 0.2; 95%CI, 0.1-0.6; P=0.004). Multivariate analyses of MFS revealed the independent risk factor to be SLC22A7 expression (OR, 0.3; 95%CI, 0.1-1.0, P=0.043). Low SLC22A7 expression caused MO of HCC significantly (log-rank, P=0.001). In the validation study, multivariate analyses of MFS revealed the independent risk factor to be SLC22A7 expression (OR, 0.5; 95%CI, 0.3-0.8; P=0.012). As judged by Gene set-enrichment analysis, SLC22A7 down-regulation associated with mitochondrion (P=0.008; false discovery rate (FDR)=0.199; normalized enrichment score (NES) =1.804), oxidoreductase activity (P=0.006; FDR=0.157; NES=1.854) and fatty acid metabolic process (P=0.021; FDR=0.177; NES=1.723). Sirtuin3 also determined MFS (P= 0.018). Conclusions: These pathways involving SLC22A7 dysfunction may promote the occurrence of HCC. The 49 noncancerous liver tissues of HCC patients within Milan criteria, treated at our institution between January 2004 and August 2008, were examined as a training set by genome-wide gene expression analysis (GA). Cox proportional hazards regression analyses for MO-free survival (MFS) were performed to estimate the risk factors. Using the independent two institutional cohorts of 134 patients between September 2008 and December 2009, a validation study was employed using tissue microarrays.

Species:
human

Samples:
49

Source:
E-GEOD-40873

Updated:
Dec.12, 2014

Registered:
Jul.12, 2014


Factors: (via ArrayExpress)
Sample PATIENT ID MULTICENTRIC OCCURRENCE-FREE SURVIVAL DAYS EVENT
GSM1003939 L165 378 no multicentric occurrence
GSM1003938 L163 396 no multicentric occurrence
GSM1003937 L157 264 no multicentric occurrence
GSM1003936 L155 258 no multicentric occurrence
GSM1003935 L154 280 no multicentric occurrence
GSM1003934 L144 1388 no multicentric occurrence
GSM1003933 L71 224 multicentric occurrence
GSM1003932 L108 648 multicentric occurrence
GSM100393 L150 368 no multicentric occurrence
GSM1003930 L147 264 multicentric occurrence
GSM1003929 L143 1044 no multicentric occurrence
GSM1003928 L141 76 multicentric occurrence
GSM1003927 L140 1427 no multicentric occurrence
GSM1003926 L137 601 no multicentric occurrence
GSM1003925 L110 340 multicentric occurrence
GSM1003924 L130 221 multicentric occurrence
GSM1003923 L134 426 multicentric occurrence
GSM1003922 L127 1338 no multicentric occurrence
GSM100392 L128 452 multicentric occurrence
GSM1003920 L126 206 multicentric occurrence
GSM1003919 L122 283 no multicentric occurrence
GSM1003918 L123 129 multicentric occurrence
GSM1003917 L121 200 no multicentric occurrence
GSM1003916 L120 87 no multicentric occurrence
GSM1003915 L111 43 no multicentric occurrence
GSM1003914 L109 64 no multicentric occurrence
GSM1003913 L107 279 no multicentric occurrence
GSM1003912 L105 1623 no multicentric occurrence
GSM10039 L104 1631 no multicentric occurrence
GSM1003910 L96 449 multicentric occurrence
GSM1003909 L90 565 no multicentric occurrence
GSM1003908 L84 734 no multicentric occurrence
GSM1003907 L80 491 multicentric occurrence
GSM1003906 L78 764 no multicentric occurrence
GSM1003905 L77 247 multicentric occurrence
GSM1003904 L76 823 no multicentric occurrence
GSM1003903 L70 267 multicentric occurrence
GSM1003902 L64 1843 no multicentric occurrence
GSM100390 L57 1901 no multicentric occurrence
GSM1003900 L53 1607 no multicentric occurrence
GSM1003899 L49 482 no multicentric occurrence
GSM1003898 L47 57 no multicentric occurrence
GSM1003897 L45 139 no multicentric occurrence
GSM1003896 L42 85 no multicentric occurrence
GSM1003895 L31 712 multicentric occurrence
GSM1003894 L18 2144 no multicentric occurrence
GSM1003893 L10 599 multicentric occurrence
GSM1003892 L08 2226 no multicentric occurrence
GSM100389 LC07 97 multicentric occurrence

Tags

  • carcinoma
  • fatty acid
  • genome
  • hepatocellular carcinoma
  • liver
  • mitochondrion

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use